Cargando…

How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience

BACKGROUND: Currently, two effective therapeutic options for severe aortic stenosis (AS) are available, one catheter-based [transcatheter aortic valve implantation (TAVI)], the other open surgical approach [surgical aortic valve replacement (SAVR)]. The COVID-19 pandemic has limited the availability...

Descripción completa

Detalles Bibliográficos
Autores principales: Perek, Bartlomiej, Olasinska-Wisniewska, Anna, Misterski, Marcin, Puslecki, Mateusz, Grygier, Marek, Buczkowski, Piotr, Lesiak, Maciej, Stankowski, Tomasz, Szarpak, Lukasz, Ruetzler, Kurt, Turan, Oguz, Jemielity, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947507/
https://www.ncbi.nlm.nih.gov/pubmed/33717563
http://dx.doi.org/10.21037/jtd-20-3025
_version_ 1783663243769675776
author Perek, Bartlomiej
Olasinska-Wisniewska, Anna
Misterski, Marcin
Puslecki, Mateusz
Grygier, Marek
Buczkowski, Piotr
Lesiak, Maciej
Stankowski, Tomasz
Szarpak, Lukasz
Ruetzler, Kurt
Turan, Oguz
Jemielity, Marek
author_facet Perek, Bartlomiej
Olasinska-Wisniewska, Anna
Misterski, Marcin
Puslecki, Mateusz
Grygier, Marek
Buczkowski, Piotr
Lesiak, Maciej
Stankowski, Tomasz
Szarpak, Lukasz
Ruetzler, Kurt
Turan, Oguz
Jemielity, Marek
author_sort Perek, Bartlomiej
collection PubMed
description BACKGROUND: Currently, two effective therapeutic options for severe aortic stenosis (AS) are available, one catheter-based [transcatheter aortic valve implantation (TAVI)], the other open surgical approach [surgical aortic valve replacement (SAVR)]. The COVID-19 pandemic has limited the availability of medical procedures. The purpose of this cross-sectional study was to assess if this pandemic had any impact on the treatment strategy of severe AS in a single cardiac center. METHODS: This study involved AS patients treated in 3-month periods (February through April) over 3 consecutive years 2018, 2019 [defined as COV(–) group] and 2020 [COV(+)]. We assessed if there were any differences regarding patients’ clinical profile, applied therapeutic method, procedure complexity and early clinical outcomes. RESULTS: In the years 2018 through 2019, approximately 50% of AS patients were treated classically (SAVR) while in 2020 this rate dropped to 34%. The preoperative clinical characteristic of TAVI subjects was comparable irrespective of the year. Regarding SAVR, more patients in COV(+) underwent urgent and more complex procedures. More of them were found in NYHA class III or IV, and had lower left ventricular ejection fraction (LVEF) (51.9%±14.4% vs. 58.3%±8.1%; P=0.021) than in COV(–) individuals. During the pandemic, a change in applied therapeutic methods and differences in patients’ clinical profile did not have an unfavorable impact on in-hospital mortality (2.0% before vs. 3.6% during pandemic) and morbidity. Of note, intubation time and in-hospital stay were significantly shorter (P<0.05) in 2020 (4.2 hours and 7.5 days) than in the previous years (7.5 hours and 9.0 days, respectively). CONCLUSIONS: The coronavirus pandemic has changed substantially the management of severe AS. The shift into less invasive treatment method of AS patients resulted in shortening of in-hospital stay without compromise of short-term outcomes.
format Online
Article
Text
id pubmed-7947507
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-79475072021-03-12 How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience Perek, Bartlomiej Olasinska-Wisniewska, Anna Misterski, Marcin Puslecki, Mateusz Grygier, Marek Buczkowski, Piotr Lesiak, Maciej Stankowski, Tomasz Szarpak, Lukasz Ruetzler, Kurt Turan, Oguz Jemielity, Marek J Thorac Dis Original Article BACKGROUND: Currently, two effective therapeutic options for severe aortic stenosis (AS) are available, one catheter-based [transcatheter aortic valve implantation (TAVI)], the other open surgical approach [surgical aortic valve replacement (SAVR)]. The COVID-19 pandemic has limited the availability of medical procedures. The purpose of this cross-sectional study was to assess if this pandemic had any impact on the treatment strategy of severe AS in a single cardiac center. METHODS: This study involved AS patients treated in 3-month periods (February through April) over 3 consecutive years 2018, 2019 [defined as COV(–) group] and 2020 [COV(+)]. We assessed if there were any differences regarding patients’ clinical profile, applied therapeutic method, procedure complexity and early clinical outcomes. RESULTS: In the years 2018 through 2019, approximately 50% of AS patients were treated classically (SAVR) while in 2020 this rate dropped to 34%. The preoperative clinical characteristic of TAVI subjects was comparable irrespective of the year. Regarding SAVR, more patients in COV(+) underwent urgent and more complex procedures. More of them were found in NYHA class III or IV, and had lower left ventricular ejection fraction (LVEF) (51.9%±14.4% vs. 58.3%±8.1%; P=0.021) than in COV(–) individuals. During the pandemic, a change in applied therapeutic methods and differences in patients’ clinical profile did not have an unfavorable impact on in-hospital mortality (2.0% before vs. 3.6% during pandemic) and morbidity. Of note, intubation time and in-hospital stay were significantly shorter (P<0.05) in 2020 (4.2 hours and 7.5 days) than in the previous years (7.5 hours and 9.0 days, respectively). CONCLUSIONS: The coronavirus pandemic has changed substantially the management of severe AS. The shift into less invasive treatment method of AS patients resulted in shortening of in-hospital stay without compromise of short-term outcomes. AME Publishing Company 2021-02 /pmc/articles/PMC7947507/ /pubmed/33717563 http://dx.doi.org/10.21037/jtd-20-3025 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Perek, Bartlomiej
Olasinska-Wisniewska, Anna
Misterski, Marcin
Puslecki, Mateusz
Grygier, Marek
Buczkowski, Piotr
Lesiak, Maciej
Stankowski, Tomasz
Szarpak, Lukasz
Ruetzler, Kurt
Turan, Oguz
Jemielity, Marek
How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience
title How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience
title_full How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience
title_fullStr How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience
title_full_unstemmed How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience
title_short How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience
title_sort how the covid-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947507/
https://www.ncbi.nlm.nih.gov/pubmed/33717563
http://dx.doi.org/10.21037/jtd-20-3025
work_keys_str_mv AT perekbartlomiej howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT olasinskawisniewskaanna howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT misterskimarcin howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT pusleckimateusz howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT grygiermarek howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT buczkowskipiotr howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT lesiakmaciej howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT stankowskitomasz howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT szarpaklukasz howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT ruetzlerkurt howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT turanoguz howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience
AT jemielitymarek howthecovid19pandemicchangedtreatmentofsevereaorticstenosisasinglecardiaccenterexperience